Daily Cardiology Research Analysis
Three impactful cardiometabolic studies stand out today. An RCT shows that adding the PCSK9 inhibitor evolocumab to statins within 24 hours of acute ischemic stroke reduces early neurological deterioration and improves 90-day outcomes. A nationwide cohort links pre-STEMI GLP-1RA use to lower long-term mortality in type 2 diabetes, while a propensity-matched analysis suggests single antiplatelet therapy after left atrial appendage closure performs comparably to dual therapy at 1 year.
Summary
Three impactful cardiometabolic studies stand out today. An RCT shows that adding the PCSK9 inhibitor evolocumab to statins within 24 hours of acute ischemic stroke reduces early neurological deterioration and improves 90-day outcomes. A nationwide cohort links pre-STEMI GLP-1RA use to lower long-term mortality in type 2 diabetes, while a propensity-matched analysis suggests single antiplatelet therapy after left atrial appendage closure performs comparably to dual therapy at 1 year.
Research Themes
- Acute-phase lipid-lowering to modify early neurological and cardiovascular outcomes
- Post–left atrial appendage closure antithrombotic optimization
- Cardiometabolic therapies (GLP-1RA) and outcomes after STEMI
Selected Articles
1. Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial.
In a multicenter PROBE RCT (n=272) of non-cardiogenic AIS within 24 hours, evolocumab plus atorvastatin reduced early neurological deterioration versus atorvastatin alone (13.2% vs 24.3%; p=0.010), increased day-7 LDL-C target attainment (74.3% vs 14.7%; p=0.001), attenuated IL-6 rise, and improved 90-day functional outcomes (mRS ≤2: 83.1% vs 65.4%). Safety profiles were comparable.
Impact: This is among the first randomized data supporting immediate PCSK9 inhibitor use in the acute stroke window, linking rapid LDL-C reduction and inflammatory modulation to early and 90-day outcomes.
Clinical Implications: For selected AIS patients within 24 hours, adding evolocumab to high-intensity statin therapy may reduce early neurological worsening and improve short-term function. Larger double-blind trials are warranted before guideline adoption.
Key Findings
- Early neurological deterioration was lower with evolocumab plus atorvastatin vs atorvastatin alone (13.2% vs 24.3%; p=0.010).
- LDL-C target attainment on day 7 was markedly higher with evolocumab (74.3% vs 14.7%; p=0.001).
- IL-6 increase over 7 days was attenuated in the evolocumab group (p=0.033), and 90-day mRS ≤2 was more frequent (83.1% vs 65.4%; p=0.001).
Methodological Strengths
- Multicenter randomized design with blinded endpoint assessment (PROBE).
- Predefined primary endpoint and mechanistic biomarkers (LDL-C targets, IL-6).
Limitations
- Open-label treatment may introduce performance bias.
- Modest sample size and single-country setting; primary follow-up limited to 7 days (clinical outcomes to 90 days).
Future Directions: Conduct large, double-blind, placebo-controlled global RCTs to confirm efficacy, assess imaging biomarkers (e.g., plaque/penumbra), and evaluate optimal timing/dosing and generalizability.
BACKGROUND: Early neurological deterioration (END) is associated with a poor prognosis in acute ischemic stroke (AIS). Effectively lowering low-density lipoprotein cholesterol (LDL-C) can improve the stability of atherosclerotic plaque and reduce post-stroke inflammation, which may be an effective means to lower the incidence of END. The objective of this study was to determine the preventive effects of evolocumab on END in patients with non-cardiogenic AIS. METHODS: This was a multicenter, prospective, open-label, blinded-endpoint clinical trial. Participants with AIS within 24 h were randomly assigned to either the group receiving combination therapy of evolocumab and atorvastatin, which is a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor, i.e., a "statin" (PI group), or the group receiving atorvastatin monotherapy (AT group). The primary outcome was END within 7 days, defined as a 2-point increase in the National Institutes of Health Stroke Scale (NIHSS) score or a 1-point increase in motor function within 24 h-7 days from the onset of AIS. Secondary outcomes included LDL-C target achievement rate on day 7 (≤ 1.8 mmol/L with a reduction exceeding 50% from baseline), inflammatory factors (interleukin [IL]-6, IL-8, and tumor necrosis factor [TNF]-α) before and after 7 days of treatment, and stroke-related death with 7 days. Safety endpoints included any adverse events. RESULTS: Patients with AIS (n = 272) were randomly assigned to the PI (n = 136) or AT (n = 136) groups. Within 7 days, 18 (13.2%) and 33 (24.3%) patients experienced END in the PI and AT groups, respectively (relative risk [RR] -0.90; 95% confidence interval [CI]: -1.59 to -0.22; p = 0.010). On the seventh day, LDL-C target achievement rate in the PI and AT groups was 74.3% and 14.7%, respectively (RR 3.27; 95% CI: 2.40-4.15; p = 0.001). Changes in IL-6 over 7 days were significantly lower in the PI group compared with the AT group, respectively (median 1.02 [range -1.91, 5.47] versus 2.54 [-0.83, 15.20]; p = 0.033). On the 90th day of follow-up, 83.1% and 65.4% of patients had a modified Rankin Scale score ≤ 2 in the PI and AT groups, respectively (RR 0.51; 95% CI: 0.66-2.66; p = 0.001). There was no significant difference in stroke recurrence between the two groups within 90 days (RR -1.72; 95% CI: -4.57 to 1.13; p = 0.237). Regarding adverse events, 15 and 22 patients in the PI and AT groups, respectively, experienced slight abnormalities in liver and kidney function laboratory values during the 7-day treatment period (odds ratio 0.62; 95% CI: 0.30-1.29; p = 0.203), but no serious adverse events were observed in either group. CONCLUSION: These results suggest that the combination therapy of evolocumab and atorvastatin within 24 h of AIS onset may effectively reduce the incidence of END compared with atorvastatin monotherapy. Additionally, in the early stages of AIS, this combination therapy can reduce blood LDL-C levels, and inhibit IL-6 elevation, potentially improving the prognosis of patients with AIS within 90 days. TRIAL REGISTRATION: China Clinical Trials Registry (No: ChicTR2200059445, 29 April 2022, https://www.chictr.org.cn/ ).
2. Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study.
In a Danish nationwide cohort of 1,421 patients with T2D and STEMI, pre-event GLP-1RA use (7% exposed) was associated with lower long-term mortality over 8.4 years (adjusted HR 0.60; 95% CI 0.43-0.84) without clear associations with stroke, recurrent MI, or HF hospitalization.
Impact: Findings support survival benefits associated with GLP-1RA therapy extending into the acute coronary event setting, reinforcing cardiometabolic strategies in high-risk populations.
Clinical Implications: For patients with T2D at risk of STEMI, sustained GLP-1RA therapy may confer long-term survival benefits. While not proving causality, the results support maintaining GLP-1RA where feasible around acute events and justify randomized trials of initiation/continuation strategies.
Key Findings
- Pre-STEMI GLP-1RA use was associated with lower long-term all-cause mortality (adjusted HR 0.60; 95% CI 0.43-0.84).
- No significant associations were seen for ischemic stroke, recurrent MI, or HF hospitalization.
- Only 7% were GLP-1RA users, yet mortality was 36% vs 52% over 8.4 years in users vs non-users (p=0.002).
Methodological Strengths
- Nationwide registry with comprehensive linkage and long follow-up (median 8.4 years).
- Adjusted Cox regression accounting for multiple comorbidities and therapies.
Limitations
- Observational design with potential residual confounding and channeling bias.
- Low exposure proportion (7%) and lack of adherence/dose information.
Future Directions: Pragmatic randomized trials testing initiation or continuation of GLP-1RA at/after STEMI; mechanistic studies to delineate infarct healing, inflammation, and arrhythmic risks.
BACKGROUND: Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes. Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on long-term prognosis in patients with type 2 diabetes remains unclear. In patients with STEMI and type 2 diabetes, we aimed to investigate the association between long-term prognosis and GLP-1RA treatment before STEMI. METHODS: This nationwide cohort study included consecutive patients admitted with type 2 diabetes and STEMI in Denmark from 2010 to 2016. All data were retrieved from nationwide Danish registries. Type 2 diabetes was defined by prior hospital admission with type 2 diabetes or anti-diabetic prescriptions within one year before STEMI. Dispensed GLP-1RA medication was retrieved within one year before STEMI. RESULTS: Of 1421 patients with STEMI and diabetes, 7% were treated with GLP-1RA before STEMI and 93% were not. Patients treated with GLP-1RA were younger, had more comorbidities, and more often treated with other anti-diabetics. During 8.4 years, 36% patients treated with GLP-1RA died whereas 52% died in the no GLP-1RA group (p = 0.002). In adjusted Cox analysis, GLP-1RA was associated with lower long-term mortality (hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.84). There was no association between GLP-1RA and ischemic stroke (adjusted HR 1.05, 95% CI 0.57-1.94), recurrent myocardial infarction (adjusted HR 0.74, 95% CI 0.48-1.15), or hospitalisation for heart failure (adjusted HR 0.71, 95% CI 0.48-1.05). CONCLUSIONS: In patients with diabetes and STEMI, GLP-1RA treatment prior to STEMI admission was associated with significantly lower long-term mortality.
3. Single vs dual antiplatelet therapy after left atrial appendage closure: A propensity score matching analysis.
In a prospectively collected single-center LAAC cohort (n=1033) with propensity score matching (SAPT n=154; DAPT n=230), the 1-year composite of cardiovascular death, stroke, systemic embolism, or DRT was similar between SAPT and DAPT. Major bleeding and DRT rates were also comparable.
Impact: Addresses a pressing clinical question in high-bleeding-risk patients after LAAC, suggesting SAPT may suffice for many patients and motivating randomized trials.
Clinical Implications: Post-LAAC antithrombotic regimens can potentially be simplified to SAPT for selected patients without increasing ischemic risk at 1 year, supporting individualized strategies pending RCT confirmation.
Key Findings
- Primary 1-year composite endpoint was similar with SAPT vs DAPT (11.0% vs 8.3%; rate ratio 1.14; 95% CI 0.83-1.55; P=0.420).
- Major bleeding did not differ (9.7% vs 12.6%; HR 0.77; 95% CI 0.43-1.39; P=0.387).
- Device-related thrombosis rates were comparable (2.6% vs 1.1%; rate ratio 1.47; 95% CI 0.89-2.43; P=0.130).
Methodological Strengths
- Prospectively collected cohort with 1-year follow-up and propensity score matching.
- Clinically relevant composite endpoints including DRT with standardized follow-up.
Limitations
- Nonrandomized single-center design with potential residual confounding.
- Potential underpowering for rare events (e.g., DRT) and device heterogeneity.
Future Directions: Adequately powered multicenter RCTs comparing SAPT vs DAPT post-LAAC, stratified by bleeding risk, device type, and imaging-guided antithrombotic tailoring.
BACKGROUND: Dual antiplatelet therapy and oral anticoagulation in combination with aspirin represent recommended treatment regimens after left atrial appendage closure (LAAC). As most patients receiving LAAC have high bleeding risk, less aggressive antithrombotic treatments are needed, such as single antiplatelet therapy. OBJECTIVE: We sought to compare both ischemic and bleeding outcomes in patients receiving single antiplatelet therapy (SAPT) or dual antiplatelet therapy (DAPT) after successful LAAC. METHODS: Data on consecutive patients undergoing percutaneous LAAC between 2009 and 2023 were prospectively collected including 1-year follow-up. Propensity score matching was performed for patients discharged under SAPT and DAPT. The primary end point was the 1-year composite of cardiovascular death, stroke, systemic embolism, or device-related thrombosis (DRT). The secondary end points included major bleeding and DRT. RESULTS: Of 1033 patients discharged with antiplatelet therapy, 154 patients receiving SAPT were compared with 230 matched patients receiving DAPT. The primary end point was similar between the study groups (SAPT 11.0% vs DAPT 8.3%; rate ratio, 1.14; 95% confidence interval [CI], 0.83-1.55; P = .420). Consistently, we found no difference in terms of both major bleeding (SAPT 9.7% vs DAPT 12.6%; hazard ratio, 0.77; 95% CI, 0.43-1.39; P = .387) and DRT (2.6% vs 1.1%; rate ratio, 1.47; 95% CI, 0.89-2.43; P = .130) between the SAPT and DAPT groups. CONCLUSION: In this propensity score matching analysis of a single-center LAAC cohort, ischemic and bleeding outcomes did not differ at 1 year for patients discharged with SAPT or DAPT. These results have to be confirmed in an adequately powered randomized clinical trial.